Esperion Therapeutics (ESPR) Stock: Flying On Late-Stage Clinical Results

With late-stage clinical results hitting the tape, Esperion Therapeutics Inc (NASDAQ: ESPR) is flying in the pre-market hours this morning. With the reaction in mind, chances are that you guessed that the results were positive, and they were overwhelmingly so. With the results in mind, excited investors are sending the stock running for the top. … Read more

Esperion Therapeutics (ESPR) Stock: Diving On Losses And Clinical Update

Esperion Therapeutics Inc (NASDAQ: ESPR) is having an overwhelmingly rough start to the trading session in the pre-market hours this morning after releasing both a clinical update and its financial results for the first quarter. While the clinical update seemed positive, there were concerns with regard to safety, and the earnings report was anything but … Read more

Esperion Therapeutics (ESPR) Stock: Gaining On Strong Clinical Data

Esperion Therapeutics Inc (NASDAQ: ESPR) is having an incredibly strong start in the pre-market hours this morning, and for good reason. The company released top-line data from a key clinical trial, and as you could imagine the data was overwhelmingly positive. This led to excitement among investors, sending the stock toward the top and prompting … Read more

Esperion Therapetuics (ESPR) Stock: Gains Big On Confirmed Regulatory Pathway

Esperion Therapeutics Inc (NASDAQ: ESPR) Esperion Therapeutics is having an overwhelmingly strong day in the market today, and for good reason. Early this morning, an announcement was made that the US FDA has confirmed a pathway toward regulatory approval for a key product in the company’s pipeline. Below, we’ll talk about what we’re seeing from … Read more

Esperion (ESPR) Stock Positioned To Capitalize On LDL-C Trials

Esperion Therapeutics Inc (NASDAQ: ESPR) Esperion has made it to the CNA Finance focus list, based on its significant market opportunity and well capitalized business structure that should offer little resistance to progressing through their stated initiatives. The company is committed to applying its scientific expertise in cholesterol biology to transform the lives of millions … Read more

Biotech Stock News (VRX) (ESPR) (REGN) (AMGN) (SRPT)

Valeant Pharmaceuticals (NYSE:VRX) On September 28, 2015 shares of Valeant closed the day down approximately 16% after congressional democrats announced that they would file a subpoena to look into the matter about the company’s high priced drugs. The two democrats that filed for this subpoena are Elijah Cummings and Bernie Sanders. More specifically these Democratic … Read more

Biotech Stock News (BIIB) (ESPR) (FOLD)

Biogen Idec (NASDAQ:BIIB) Shares of Biogen soared as much as 10% on Friday March 20, 2015 after the company reported that it had achieved a positive outcome in an early phase 1b trial in patients with Alzheimer’s. Matter in fact many Wall Street analysts were expecting a weak efficacy outcome but Biogen’s drug BIIB037 went … Read more